Excellent
Fully Aligned
Patient Risk:
Low
Summary
All evaluated claims in the AI-provided content are directly supported by the cited ENTRESTO label sections (5.1, 8.1, and 17) with no contradictions.
Category Scores
Accurate Statements
ENTRESTO can cause fetal harm when administered during pregnancy.
ENTRESTO prescribing information Section 5.1 and Section 8.1 Risk Summary
Use of drugs that act on the renin-angiotensin system during the second and third trimesters reduces fetal renal function and increases fetal and neonatal morbidity and death.
Section 5.1 and Section 8.1 Risk Summary
When pregnancy is detected, consider alternative drug treatment and discontinue ENTRESTO.
Section 5.1 and Section 8.1 Risk Summary
If there is no appropriate alternative and the drug is considered lifesaving for the mother, advise a pregnant woman of the potential risk to the fetus.
Section 5.1 and Section 8.1 Risk Summary
Pregnancy counseling should include consequences of exposure to ENTRESTO and advising patients to report pregnancies to their physicians as soon as possible.
Section 17 (Pregnancy counseling) with cross-reference to Sections 5.1 and 8.1
Unsupported Statements
Contradictions
Important Omissions
No evaluation provided for boxed warnings, dosage/administration, contraindications, drug interactions, adverse reactions, or monitoring/storage, because none were asserted in the AI response. (Non-applicable to the pregnancy-only content requested.)
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The content evaluated pertains to pregnancy fetal harm risk and label-consistent counseling/discontinuation language; no incorrect or contradictory safety claims were made.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Fully Aligned
Primary Issue
Suggested Improvement